Skip to main content
. Author manuscript; available in PMC: 2023 Feb 14.
Published in final edited form as: Biomed J Sci Tech Res. 2022 Feb 14;41(5):33086–33092. doi: 10.26717/BJSTR.2022.41.006668

Table 3:

Quantitative benchmarks for clinical practice management

Characteristic Value (%) [95% CI]
Percentage of initial BI-RADS 3 to total screens 1,037/135,765 (0.76%) [ 0.72% - 0.81%]
Percentage of initial BI-RADS 3 to screen-recalled (BI-RADS 0) cases 1,037/13,453 (7.71%) [7.26% - 8.17%]
Upgrade rate within 24 months of BI-RADS 3 77/1,037 (7.43%) [5.90% - 9.19%]
PPV3 of biopsies within 24 months of BI-RADS 3 26/77 (33.77%) [23.38% - 45.45%]
Cancer yield within 24 months of BI-RADS 3 26/1,037 (2.51%) [1.64% - 3.65%]
Cancer type
Ductal carcinoma in situ (DCIS) 12/26 (46.2%) [26.6% - 66.6%]
Invasive ductal carcinoma (IDC) 11/26 (42.3%) [23.4% - 63.1%]
Invasive lobular carcinoma (ILC) 3/26 (11.5%) [2.5% - 30.2%]